Calamos Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Calamos Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-74,119	Closed	-$2.9M	–	630
2013 Q2	$2.9M	Buy	+74,119	New	+$2.89M	0.02%	355

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Calamos Advisors's TEVA Position: Q3 2013 in Review

Calamos Advisors sold out of Teva Pharmaceuticals (TEVA) in Q3 2013, closing a stake of 74,119 shares — an estimated $2.9M sold.

Calamos Advisors first reported a position in TEVA in Q2 2013 and held it in 1 quarter. The position peaked at $2.9M in Q2 2013. 705 funds tracked by Wall St. Rank hold TEVA as of Q3 2013.

Calamos Advisors reported no remaining Teva Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
Calamos Advisors sold 74,119 Teva Pharmaceuticals shares in Q3 2013, an estimated $2.9M.
Calamos Advisors first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 1 quarter.
Calamos Advisors's Teva Pharmaceuticals position peaked at $2.9M in Q2 2013.
705 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2013.

Based on Calamos Advisors's 13F filing for Q3 2013, filed 14 Nov 2013.